Hepion Pharmaceuticals grants chairman 1.53M options

The award vests in equal monthly amounts of 127,500 options over 12 months from the grant date.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. Executive Chairman Vincent S. LoPriore was granted 1,530,000 stock options on October 23, 2026. The options have an exercise price of $0.14 per share and expire October 23, 2036. LoPriore's reported direct option holdings following the award were 2,875,500.

Insider Trade Summary

Grant/Award: 1,530,000 shares

Grant/Award 1 txn

Insider LoPriore Vincent S

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	1,530,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 2,875,500 contracts (Direct)

Footnotes (1)

1. F1. 127,500 options vest in equal amounts monthly over 12 months from date of grant.

Key Figures

Stock options granted: 1,530,000 stock options Exercise price: $0.14 per share Monthly vesting: 127,500 options +3 more

6 metrics

Stock options granted 1,530,000 stock options Granted October 23, 2026

Exercise price $0.14 per share Option award

Monthly vesting 127,500 options Equal monthly amounts from the grant date

Vesting period 12 months From the grant date

Direct option holdings after award 2,875,500 options Reported following the grant

Expiration date October 23, 2036 Option award

Key Terms

Stock Options, exercise price, vest

3 terms

Stock Options financial

"the 1,530,000 stock options granted to the Executive Chairman"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"the options have an exercise price of $0.14 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"options vest in equal amounts monthly over 12 months"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did HEPA Executive Chairman Vincent S. LoPriore receive?

Hepion Pharmaceuticals, Inc. Executive Chairman Vincent S. LoPriore was granted 1,530,000 stock options on October 23, 2026.

What are the vesting terms for HEPA's option award?

127,500 options vest in equal monthly amounts over 12 months from the grant date. The options have an exercise price of $0.14 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:31 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LoPriore Vincent S

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

22 WEST STREET, SUITE 1B

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.14	10/23/2026		A		1,530,000		(1)	10/23/2036	Common Stock	1,530,000	$0	2,875,500	D

Explanation of Responses:

1. 127,500 options vest in equal amounts monthly over 12 months from date of grant.

	/s/ Vincent LoPriore	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)